Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Breast Neoplasms 2Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1

Interventions

Etoposide 34Carboplatin 31Topotecan 24Cisplatin 21atezolizumab 11PM 01183 8durvalumab 7Irinotecan 7amrubicin 5PE regimen 4AMG 757 4rovalpituzumab tesirine 3pembrolizumab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3tremelimumab 2tislelizumab 2etoposide phosphate 2apatinib 2Vitamin E 2Tiragolumab 2Specimen Handling 2Radiosurgery 2RRx-001 2Paclitaxel 2Memantine 2Injections 2EC regimen 2trilaciclib 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Small Cell Lung Carcinoma × EC regimen × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00812266 2016-01-26

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Danish Oncological Lung Cancer Group

Phase 3 Terminated
281 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡